Disclaimer: Note that the firm is no longer accepting cases for the anti-psychotic medication Abilify or Tylenol autism cases. Thank you.
Select Page

CPAP Multidistrict Litigation Has its First Judicial Hearing

Litigation
The first-class action was filed in the District of Massachusetts on June 17, 2021. The first plaintiff lung cancer case was filed in the middle district of Georgia on July 2 of 2021. The Multidistrict Litigation that was formed is MDL 3014. The appearance deadline of which was July 22, 2021. On September 30, CPAP Litigation had its first JPML hearing, which is the Judicial Panel on Multidistrict Litigation.

Qualifying Injuries
There are several qualifying injuries currently under this particular multi-district litigation. They are listed here below:
• kidney disease or damage
• liver disease or damage
• lung disease or damage
• respiratory failure
• reactive airway disease
• acute respiratory distress system
• pleural effusion
• chemical poisoning
• bladder cancer
• brain cancer
• breast cancer
• kidney cancer
• leukemia
• liver cancer
• lung cancer
• lymphatic cancer
• multiple myeloma
• non-Hodgkin’s lymphoma
• prostate cancer
• rectal cancer
• stomach cancer
• testicular cancer
• thyroid cancer
• esophageal cancer

Current Criteria
The current criteria for a plaintiff are as follows: the plaintiff must have used Phillips Resporal onyx CPAP, APAP, or BiPAP device or a mechanical ventilator; the plaintiff must have used the qualifying device for at least six months.

If you or a loved one have been injured by a CPAP device, please call us at the Michael Brady Lynch Firm at 888-585-5970.

Sources:

https://www.fda.gov/medical-devices/medical-device-recalls/philips-respironics-recalls-certain-continuous-and-non-continuous-ventilators-including-cpap
https://www.fiercebiotech.com/medtech/fda-dishes-out-class-i-label-to-philips-recall-faulty-cpap-machines-and-other-ventilators

 

Injured on a Cruise Ship? Call Us

Injured on a Cruise Ship? Call Us

Cruise vacations promise relaxation and adventure, but accidents do happen. Injuries aboard cruise ships can range from minor incidents to severe accidents, raising complicated legal questions about liability and compensation.

read more
Suboxone Lawsuits: From Opioid Addiction Cure to MDL Defendant

Suboxone Lawsuits: From Opioid Addiction Cure to MDL Defendant

According to the National Center for Biotechnology Medicine, more people die from drug overdoses in the US than any other form of accidental death. Opioid overdoses outnumber the historical peak death rate of HIV, gun violence, and car crashes. There’s no doubt we’re in the middle of an opioid crisis. Often, people become addicted to this drug after a legitimate prescription to manage pain after surgery or a chronic pain condition.

read more
Video Game Lawsuits: Developers Face Legal Action for Addictive Gameplay

Video Game Lawsuits: Developers Face Legal Action for Addictive Gameplay

Over the past 20 to 30 years, studies and mainstream media outlets have blamed video games for desensitizing minors to violence, increased obesity rates, sedentary lifestyles, and mental health issues like depression and anxiety. Now, developers are facing video game lawsuits from gamers who have become addicted to video games. Learn more about video game addiction and what to do if you or a loved one have suffered from video game addiction below.

read more
Ozempic Lawsuit 2024: The Latest Updates

Ozempic Lawsuit 2024: The Latest Updates

The FDA has approved Ozempic, a medication manufactured by Dutch company Novo Nordisk, for treating type 2 diabetes. Many healthcare providers also prescribe Ozempic to their patients for weight management purposes. This is because the medication’s active ingredient, semaglutide, has been approved for weight loss treatments.

read more
PFAS Lawsuit Update: March 2024

PFAS Lawsuit Update: March 2024

Suboxone, a medication approved by the FDA for the treatment of opioid addiction, has garnered significant attention not just within medical circles but also in legal domains. Composed of buprenorphine and naloxone, Suboxone has been lauded for its effectiveness in reducing opioid withdrawal symptoms and cravings. However, its rise in use has been shadowed by a growing concern over its potential for abuse, dependency, and the risk of serious side effects.

read more
×
What Our Clients Are Saying